Latest Breaking News On - Multiple ascending dose - Page 9 : comparemela.com

ConSynance Therapeutics Reports Positive Phase 1 Results for CSTI-500 in Prader-Willi Syndrome Patients

ConSynance Therapeutics Reports Positive Phase 1 Results for CSTI-500 in Prader-Willi Syndrome Patients
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNew yorkConsynance therapeutics incFounder consynance therapeutics incVanderbilt medical centerSarah sheldrick consynance therapeutics incWall streetSynance therapeuticsPrader willi syndromeTriple monoamine reuptake inhibitorAscending doseMultiple ascending doseShuang liuConsynance therapeuticsNew chemical entityNew york based

Regulus Therapeutics Reports First Quarter 2023 Financial Results and Recent Updates

/PRNewswire/ Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines.

United statesSan diegoCris calsadaSarah suttonJay haganRegulus therapeutics incProgram updatesRnas the company or regulusEnterprise associatesDevelopment rd expensesExchange commissionAutosomal dominant polycystic kidney diseaseMultiple ascending dosePrivate placementFederated hermes kaufmann fundsNew enterprise associates

Regulus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Updates

/PRNewswire/ Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines.

United statesSan diegoMorgan carlsonEdmund leeClaire padgettRekha gargJay haganRegulus therapeutics incChronic kidney disease drug development summitProgram updatesRnas the company or regulusClinical developmentExchange commissionPrnewswire regulus therapeutics incDevelopment rd expensesMultiple ascending dose

Regulus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Updates

Enrollment progressing in Phase 1b Multiple-Ascending Dose (MAD) study of RGLS8429 in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) Top-line data in the first cohort of RGLS8429-treated ADPKD patients anticipated in second half of .

United statesSan diegoMorgan carlsonEdmund leeClaire padgettRekha gargJay haganDevelopment rd expensesPrnewswire regulus therapeutics incExchange commissionClinical developmentRnas the company or regulusProgram updatesRegulus therapeutics incChronic kidney disease drug development summitMultiple ascending dose

Codexis (CDXS) and Nestlé Health Science Announce Interim Results from Phase 1 Clinical Trial of CDX-7108

Codexis (CDXS) and Nestlé Health Science Announce Interim Results from Phase 1 Clinical Trial of CDX-7108
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Lauren mustoHans juergen woerleCarrie mckimExchange commissionHealth scienceCodexis incHealth science nhscWall streetStephen dillyChief executive officerChief scientificMedical officerInterim analysisSerious adverse eventsSingle ascending doseMultiple ascending dose